Xilio Therapeutics, Inc. Stock Analysis & AI Score
Xilio Therapeutics, Inc. (XLO) has an ST Score of 62.2 (B), driven by its Growth (A) and held back by its Financial Strength (D+). Analysts rate it Buy with a $98.00 price target (+988.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Xilio Therapeutics, Inc. (XLO) has an ST Score of 62.2 (B), driven by its Growth (A) and held back by its Financial Strength (D+). Analysts rate it Buy with a $98.00 price target (+988.9% upside).
- Strongest
- GrowthA
- Weakest
- Financial StrengthD+
All factor grades
- GrowthA
- ForecastA
- MomentumA-
- ValuationB
- ProfitabilityB
- Financial StrengthD+
- Piotroski3/9
Contact
XLO stock: frequently asked questions
What is XLO's ST Score?
Xilio Therapeutics, Inc. (XLO) has an ST Score of 62.2 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is XLO a buy, hold, or sell?
Analysts rate XLO a Buy, with a price target of $98.00 (+988.9% vs the current price). Our ST Score grades it B (62.2/100). The ST Score is a data-driven signal, not a recommendation.
What are XLO's factor grades?
Valuation B, Profitability B, Financial Strength D+, Momentum A-, Growth A, Forecast A.
What is XLO's valuation grade?
Xilio Therapeutics, Inc. (XLO) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is XLO's growth grade?
Xilio Therapeutics, Inc. (XLO) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is XLO's profitability grade?
Xilio Therapeutics, Inc. (XLO) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is XLO's financial strength grade?
Xilio Therapeutics, Inc. (XLO) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for XLO?
The average analyst price target for Xilio Therapeutics, Inc. (XLO) is $98.00 from 3 analysts, which is +988.9% versus the recent price of $9.00.
What is XLO's Piotroski score?
Xilio Therapeutics, Inc. (XLO) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.